Jul 8, 2026 07:36AM
Jul 8, 2026 07:35AM
May 14, 2026 08:00AM
Mar 19, 2026 08:00AM
Feb 17, 2026 08:00AM
Dec 2, 2025 08:01AM
Dec 2, 2025 08:00AM Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Nov 24, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 08:00AM
Aug 21, 2025 08:00AM
Aug 14, 2025 08:00AM
Jun 30, 2025 08:00AM Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Jun 11, 2025 08:00AM
Jun 3, 2025 08:01AM
Jun 3, 2025 08:00AM
May 15, 2025 08:00AM
May 5, 2025 08:03AM
May 5, 2025 08:00AM
Apr 28, 2025 08:03AM Chemomab Therapeutics (CMMB) Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Apr 28, 2025 08:00AM
Apr 21, 2025 08:00AM
Apr 15, 2025 08:00AM
Mar 27, 2025 08:30AM
Mar 27, 2025 08:30AM
Mar 6, 2025 08:00AM
Mar 3, 2025 08:00AM Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Feb 19, 2025 07:00AM
Feb 19, 2025 07:00AM
Feb 3, 2025 07:00AM
Dec 3, 2024 07:00AM
Nov 19, 2024 07:00AM
Nov 14, 2024 07:00AM
Nov 14, 2024 07:00AM Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 30, 2024 07:00AM
Oct 15, 2024 07:01AM
Oct 15, 2024 07:00AM
Oct 1, 2024 07:00AM
Aug 21, 2024 07:00AM
Jul 25, 2024 07:01AM
Jul 25, 2024 07:00AM Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients
Jun 18, 2024 07:03AM
Jun 18, 2024 07:00AM
May 9, 2024 07:00AM
Apr 2, 2024 07:00AM
Mar 25, 2024 07:07AM
Mar 25, 2024 07:06AM
Mar 7, 2024 07:00AM Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Feb 20, 2024 07:10AM

325,896 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All